HIKMA Pharmaceuticals PLC — Director's Dealing 2015

Mar 19, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9336H

Hikma Pharmaceuticals Plc

19 March 2015

Hikma Pharmaceuticals PLC - Vesting of 2012 LTIP

LONDON, 19 March 2015: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 19 March 2015 under the 2005 Long Term Incentive Plan ("LTIP"). These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is £nil. The persons concerned have retained all the shares exercised.

In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over the Company's Ordinary Shares of 10p each as detailed below.

Bassam Kanaan	Vesting of LTIP 2012	46,300 (0.02% ISC)	19 March 2015	£22.26	Nil	500,390 (0.25% ISC)
Michael Raya	Vesting of LTIP 2012	43,800 (0.02% ISC)	19 March 2015	£22.26	Nil	119,960 (0.06% ISC)
Riad Mishlawi	Vesting of LTIP 2012	20,700 (0.01% ISC)	19 March 2015	£22.26	Nil	100,027 (0.05% ISC)
Khalid Nabilsi	Vesting of LTIP 2012	26,000 (0.01% ISC)	19 March 2015	£22.26	Nil	222,858 (0.11% ISC)
"ISC" = Issued Share Capital of Hikma which is 198,879,939 Ordinary Shares following the release of the LTIP 2012

- ENDS -

Enquiries                                                                                                                                      

Peter Speirs                                                                          +44 20 7399 2760

Company Secretary, Hikma Pharmaceuticals PLC

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.  

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBXGDXSSBBGUC